<DOC>
	<DOC>NCT01050348</DOC>
	<brief_summary>This is a double-blinded randomized placebo controlled trial investigating the role of upstream 80mg Atorvastastin-calcium in patients undergoing percutaneous intervention for acute STEMI.</brief_summary>
	<brief_title>To Investigate the Role of Upstream High Dose Statin in STEMI</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1. Any patient of 25 to 90 years of age admitted or transferred to Western Pennsylvania Hospital or Allegheny General Hospital with a diagnosis of STEMI undergoing emergent percutaneous intervention (PCI) to the culprit coronary artery. STEMI is defined as greater than 1mm ST segment elevation on electrocardiogram. 2. Elevated cardiac biomarkers (troponinT &gt; 0.03ng/ml, CKMB&gt;5ng/mL, or ck&gt;170 U/l). 1. Known history of liver disease defined as cirrhosis, alcoholic liver disease, Non alcoholic steatohepatitis, hepatitis or any causes of liver failure. 2. Renal failure with creatinine &gt;3mg/dL 3. Known history of liver or muscle disease such as rheumatologic myopathies, history of myositis, hepatitis, and hepatic cancer. 4. Cardiovascular arrest and shock.</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>